



Contents lists available at ScienceDirect

## Vaccine

journal homepage: [www.elsevier.com/locate/vaccine](http://www.elsevier.com/locate/vaccine)

## Corrigendum

## Corrigendum to “One or two doses of live varicella virus-containing vaccines: Efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life” [Vaccine 36 (2018) 381–387] <sup>☆</sup>



Ouzama Henry <sup>a</sup>, Jerzy Brzostek <sup>b</sup>, Hanna Czajka <sup>c</sup>, Giedra Leviniene <sup>d</sup>, Olga Reshetko <sup>e</sup>, Roberto Gasparini <sup>f</sup>, Petr Pazdiora <sup>g</sup>, Doina Plesca <sup>h</sup>, Maria Giuseppina Desole <sup>i</sup>, Rimantas Kevalas <sup>d</sup>, Giovanni Gabutti <sup>j</sup>, Michael Povey <sup>k,\*</sup>, Bruce Innis <sup>a</sup>

<sup>a</sup> Vaccine Discovery and Development, GSK, Philadelphia, United States

<sup>b</sup> Poradnia Chorób Zakaźnych ZOZ Dębica, Dębica, Poland

<sup>c</sup> Infectious Diseases Outpatient Clinic, The St. Luis Provincial Specialist Children's Hospital, Cracow, Poland

<sup>d</sup> Pediatric Clinic, Lithuanian University of Health Sciences, Kaunas, Lithuania

<sup>e</sup> Pharmacology, Saratov Medical University, Saratov, Russia

<sup>f</sup> Department of Health Sciences, Genoa University, Genoa, Italy

<sup>g</sup> Department of Epidemiology, Medical Faculty Pilsen of Charles University, Czech Republic

<sup>h</sup> Pediatrics, University of Medicine and Pharmacy, Bucharest, Romania

<sup>i</sup> Servizio di Igiene Pubblica, ASL Sassari, Italy

<sup>j</sup> Department of Medical Sciences, University of Ferrara, Ferrara, Italy

<sup>k</sup> Biostatistics, GSK, Wavre, Belgium

The authors regret to inform that in the last paragraph of the Section 3.2. describing the vaccine efficacy the section:

“There were three confirmed HZ cases (one in MMR + V group and two in MMR group); all were mild and all children had a previous PCR-confirmed varicella case; three confirmed HZ cases tested positive for the wild-type virus. The interval between the onset of primary disease and the onset of HZ was between 15 and 57 months. Two cases (one in MMR + V and one in MMR group) had papular and one (MMR group) had vesicular lesions.” is incorrect due to a mistake in the number of confirmed HZ cases reported. The correct section is:

“There were four confirmed HZ cases (two in MMR + V group and two in MMR group); all were mild and all children had a pre-

vious PCR-confirmed varicella case; three confirmed HZ cases tested positive for the wild-type virus. The interval between the onset of primary disease and the onset of HZ was between 15 and 57 months. Two cases (one in MMR + V and one in MMR group) had papular and two cases (one in MMR + V and one in MMR group) had vesicular lesions.”

While this does not impact neither the results of the study and its significance nor the conclusion, we thought that was important to notify it in order to be aligned with what is mentioned in the conclusion of the abstract.

The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.vaccine.2017.11.081>

<sup>☆</sup> **Previous congress activities, if any:** Partial data were presented as an abstract and presentation at the 33rd European Society for Paediatric Infectious Diseases Conference (May 2015, Leipzig, Germany).

\* Corresponding author at: GSK, Avenue Fleming 20, 1300 Wavre, Belgium.

E-mail addresses: [ouzama.n.henry@gsk.com](mailto:ouzama.n.henry@gsk.com) (O. Henry), [jerzy\\_br@poczta.onet.pl](mailto:jerzy_br@poczta.onet.pl) (J. Brzostek), [hanna.czajka@onet.pl](mailto:hanna.czajka@onet.pl) (H. Czajka), [giedrale@gmail.com](mailto:giedrale@gmail.com) (G. Leviniene), [reshetko@yandex.ru](mailto:reshetko@yandex.ru) (O. Reshetko), [gasparini@unige.it](mailto:gasparini@unige.it) (R. Gasparini), [PAZDIORA@fnplzen.cz](mailto:PAZDIORA@fnplzen.cz) (P. Pazdiora), [doinaplesca@yahoo.com](mailto:doinaplesca@yahoo.com) (D. Plesca), [madesole@aslssassari.it](mailto:madesole@aslssassari.it) (M.G. Desole), [rimantas.kevalas@kaunoklinikos.lt](mailto:rimantas.kevalas@kaunoklinikos.lt) (R. Kevalas), [giovanni.gabutti@unife.it](mailto:giovanni.gabutti@unife.it) (G. Gabutti), [michael.x.povey@gsk.com](mailto:michael.x.povey@gsk.com) (M. Povey), [innisb00@gmail.com](mailto:innisb00@gmail.com) (B. Innis).

<https://doi.org/10.1016/j.vaccine.2018.09.022>

0264-410X/© 2018 GlaxoSmithKline SA. Published by Elsevier Ltd.

This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).